Results 151 to 160 of about 1,301,949 (212)

Budget impact analysis of including biosimilar adalimumab on formulary: A US payer perspective. [PDF]

J Manag Care Spec Pharm
McGill S.
europepmc   +1 more source

Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States. [PDF]

Infect Dis Ther
Wilson M, Golan Y, Nguyen D, Yazdani M, Amin AN.   +4 more
europepmc   +1 more source

Budget impact analysis of cabergoline for medical treatment of Cushing's disease in Brazil. [PDF]

Arch Endocrinol Metab
Silva LFO, Galendi JSC, Martins MRA, Nogueira VDSN.   +3 more
europepmc   +1 more source

A budget impact analysis of gene therapy for sickle cell disease: an updated analysis. [PDF]

Blood Adv
DeMartino PC, Haag MB, Caughey AB, Roth JA.   +3 more
europepmc   +1 more source

Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis. [PDF]

Front Pharmacol
Berti G, Mengato D, Ocagli H, Chinellato G, Mazzitelli M, Cattelan AM, Baldi I, Venturini F.   +7 more
europepmc   +1 more source

Cost-effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting. [PDF]

J Comp Eff Res
Subash R, Strakosch T, Zhang M, Hagan M, Dworatzek E, Kisser A, Vasilopoulos V, Salter C, Dickerson C, Stawowczyk E.   +9 more
europepmc   +1 more source